Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B

Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current international CHB guidelines recommend antiviral treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Young-Suk, Kim, W. Ray, Dieterich, Douglas, Kao, Jia-Horng, Flaherty, John F., Yee, Leland J., Roberts, Lewis R., Razavi, Homie, Kennedy, Patrick T. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142077/
https://www.ncbi.nlm.nih.gov/pubmed/37112976
http://dx.doi.org/10.3390/v15040997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142077/
https://www.ncbi.nlm.nih.gov/pubmed/37112976
http://dx.doi.org/10.3390/v15040997

Ejemplares similares